Christopher M. Blanchette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher M. Blanchette has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Benjamin Gutierrez
3 shared publicationsLinda Simoni-Wastila
Peter Lamy Center on Drug Therapy and Aging
3 shared publicationsManabu Akazawa
Department of Health Policy and Administration, University of North Carolina at Chapel Hill, School of Public Health, Chapel Hill, North Carolina
3 shared publicationsAnand A. Dalal
GlaxoSmithKline, Res Triangle Pk, NC USA
2 shared publicationsAnand Dalal
US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA
2 shared publicationsBruce Stuart
Peter Lamy Center on Drug Therapy and Aging, Department of Pharmaceutical Health Services Research, University of Maryland Baltimore School of Pharmacy
2 shared publications
Latest Publications
- 1 March 2011
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 17 (2) , 84-89
Advances in chronic obstructive pulmonary disease among older adults
This review summarizes recent research on chronic obstructive pulmonary disease (COPD) among older adults. Recent research on COPD and older adults addresses four key areas: diagnosis and screening, comorbidities, end-of-life care, and management. These key findings include the Rotterdam study's identification of the incidence rate of COPD in older adults being 9.2 per 1000 person-years; a new assessment of FEV1 cut-points associated with increased prevalence of respiratory symptoms and risk of death; development and validation of new mortality scales, the ADO (age, dyspnea, and airflow obstruction) index and the PILE score; older adults with COPD average 9 comorbidities, of which depression, cardiovascular diseases such as hypertension, and chronic renal failure are highly prevalent; nonrespiratory treatments such as proton pump inhibitors, angiotensin-converting enzyme inhibitors, and statins show promise in the management of COPD; and strength may be a protective factor for older adults with COPD. Findings suggest that more research on older adults and COPD suggest that aging is a determinant of the progression of disease and that management of this population requires different metrics and strategies.
- 1 March 2011
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 17 (2) , 84-89
Advances in chronic obstructive pulmonary disease among older adults
This review summarizes recent research on chronic obstructive pulmonary disease (COPD) among older adults. Recent research on COPD and older adults addresses four key areas: diagnosis and screening, comorbidities, end-of-life care, and management. These key findings include the Rotterdam study's identification of the incidence rate of COPD in older adults being 9.2 per 1000 person-years; a new assessment of FEV1 cut-points associated with increased prevalence of respiratory symptoms and risk of death; development and validation of new mortality scales, the ADO (age, dyspnea, and airflow obstruction) index and the PILE score; older adults with COPD average 9 comorbidities, of which depression, cardiovascular diseases such as hypertension, and chronic renal failure are highly prevalent; nonrespiratory treatments such as proton pump inhibitors, angiotensin-converting enzyme inhibitors, and statins show promise in the management of COPD; and strength may be a protective factor for older adults with COPD. Findings suggest that more research on older adults and COPD suggest that aging is a determinant of the progression of disease and that management of this population requires different metrics and strategies.
- Open Access
- 1 January 2011
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 6, 73-81
Economic burden of chronic bronchitis in the United States: a retrospective case-control study
Peer reviewed article authored by (Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al ). Read article or submit your manuscript for publishing.
- 1 January 2011
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 6, 73-81
Open AccessEconomic burden of chronic bronchitis in the United States: a retrospective case-control study
Peer reviewed article authored by (Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al ). Read article or submit your manuscript for publishing.
- 1 January 2011
- Vol. 17 (1) , 19-27
Relationship between short-acting β2-adrenergic agonist use and healthcare costs.
To assess whether increased short-acting β(2)-adrenergic agonist (SABA) claims are associated with asthma exacerbations and increased healthcare costs. Cross-sectional study. Patients (N = 93,604) were health plan members aged 6-56 years with at least 2 years of enrollment between July 1, 2003, and June 30, 2007, an asthma diagnosis, and at least 1 asthma medication claim per study year. Two years of administrative claims were collected. SABA use was categorized as 0 (none), (1/2) to 2 (low), 2(1/2) to 6 (moderate), 6(1/2) to 12 (high), and more than 12 (excessive) canister equivalents per year. Multivariate analyses were adjusted for age, sex, geographic region, comorbidities, specialist consultation, controller medication use, and asthma severity. Half of high and excessive SABA users had few or no controller claims. Compared with SABA nonusers, high and excessive SABA users had significantly higher odds (odds ratio [95% confidence interval]) of asthma-related emergency department/urgent care visits (6.47 [5.25, 7.98] and 7.68 [6.04, 9.76], respectively), hospitalizations (5.37 [6.04, 9.76]; 6.90 [4.90, 9.73]), and oral corticosteroid use (2.89 [2.72, 3.08]; 3.71 [3.41, 4.03]). Excessive SABA users had 3.0 times ($1791) and high SABA users had 2.2 times ($1326) higher asthma-related healthcare costs than low SABA users ($595). Total costs also increased with higher SABA use, but with smaller incremental differences between excessive and high SABA users and low SABA users. Increased SABA use is associated with higher total and asthma-related healthcare costs. Opportunity exists to lessen overreliance on SABAs.
- 1 January 2011
- Vol. 17 (1) , 19-27
Relationship between short-acting β2-adrenergic agonist use and healthcare costs.
To assess whether increased short-acting β(2)-adrenergic agonist (SABA) claims are associated with asthma exacerbations and increased healthcare costs. Cross-sectional study. Patients (N = 93,604) were health plan members aged 6-56 years with at least 2 years of enrollment between July 1, 2003, and June 30, 2007, an asthma diagnosis, and at least 1 asthma medication claim per study year. Two years of administrative claims were collected. SABA use was categorized as 0 (none), (1/2) to 2 (low), 2(1/2) to 6 (moderate), 6(1/2) to 12 (high), and more than 12 (excessive) canister equivalents per year. Multivariate analyses were adjusted for age, sex, geographic region, comorbidities, specialist consultation, controller medication use, and asthma severity. Half of high and excessive SABA users had few or no controller claims. Compared with SABA nonusers, high and excessive SABA users had significantly higher odds (odds ratio [95% confidence interval]) of asthma-related emergency department/urgent care visits (6.47 [5.25, 7.98] and 7.68 [6.04, 9.76], respectively), hospitalizations (5.37 [6.04, 9.76]; 6.90 [4.90, 9.73]), and oral corticosteroid use (2.89 [2.72, 3.08]; 3.71 [3.41, 4.03]). Excessive SABA users had 3.0 times ($1791) and high SABA users had 2.2 times ($1326) higher asthma-related healthcare costs than low SABA users ($595). Total costs also increased with higher SABA use, but with smaller incremental differences between excessive and high SABA users and low SABA users. Increased SABA use is associated with higher total and asthma-related healthcare costs. Opportunity exists to lessen overreliance on SABAs.
- 16 August 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (10) , 2421-2429
Adherence to controller therapy for chronic obstructive pulmonary disease: a review
Objective: While several studies have examined adherence to controller medications for the treatment of COPD, few systematic reviews have taken the translational step to identifying important and necessary areas for further research. The objective of this study was to review data on the outcomes of adherence to various controller therapies in patients with COPD in an effort to help prescribers understand adherence properties for each therapy. Research design and methods: This is a systematic review of studies investigating adherence to an array of controller pharmaceutical regimens. The studies were obtained from PubMed during 2008 and 2009 using the following key words: chronic obstructive pulmonary disease, COPD, adherence, controller medication, and persistence. Only articles encompassing adherence or persistence data to controller medications and published after 1990 were utilized. Results: After the search results were filtered for only the articles that pertained to adherence or persistence measurements in COPD, 35 articles remained; and finally, discounting those articles not published in English, articles which did not compare treatments for COPD, as well as those which were review articles, ten applicable articles remained. Each of these found low levels of medication adherence and/or persistence among patients receiving medications for COPD. Patients receiving fluticasone/salmeterol (FSC) and tiotropium (TIO) for treatment showed the highest adherence among all controller medications. Patients who were married, older, and white were more likely to adhere to their medications. Conclusion: Characteristics of the medication used (i.e. dosing schedule, formulation, etc.) as well as patient characteristics affect the adherence/persistence to medications for the treatment of COPD. Further patient education is necessary in order to effectively improve disease management and patient outcomes in COPD. There is a need for future research and educational efforts to improve adherence in COPD and more clearly identify specific behavioral and treatment characteristics associated with specific COPD medications that can facilitate adherence.
- 16 August 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (10) , 2421-2429
Adherence to controller therapy for chronic obstructive pulmonary disease: a review
Objective: While several studies have examined adherence to controller medications for the treatment of COPD, few systematic reviews have taken the translational step to identifying important and necessary areas for further research. The objective of this study was to review data on the outcomes of adherence to various controller therapies in patients with COPD in an effort to help prescribers understand adherence properties for each therapy. Research design and methods: This is a systematic review of studies investigating adherence to an array of controller pharmaceutical regimens. The studies were obtained from PubMed during 2008 and 2009 using the following key words: chronic obstructive pulmonary disease, COPD, adherence, controller medication, and persistence. Only articles encompassing adherence or persistence data to controller medications and published after 1990 were utilized. Results: After the search results were filtered for only the articles that pertained to adherence or persistence measurements in COPD, 35 articles remained; and finally, discounting those articles not published in English, articles which did not compare treatments for COPD, as well as those which were review articles, ten applicable articles remained. Each of these found low levels of medication adherence and/or persistence among patients receiving medications for COPD. Patients receiving fluticasone/salmeterol (FSC) and tiotropium (TIO) for treatment showed the highest adherence among all controller medications. Patients who were married, older, and white were more likely to adhere to their medications. Conclusion: Characteristics of the medication used (i.e. dosing schedule, formulation, etc.) as well as patient characteristics affect the adherence/persistence to medications for the treatment of COPD. Further patient education is necessary in order to effectively improve disease management and patient outcomes in COPD. There is a need for future research and educational efforts to improve adherence in COPD and more clearly identify specific behavioral and treatment characteristics associated with specific COPD medications that can facilitate adherence.
- Open Access
- 1 June 2010
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 5, 179-187
Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
Peer reviewed article authored by (Anand A Dalal, Meaghan St Charles, Hans V Petersen, et al). Read article or submit your manuscript for publishing.
- 1 June 2010
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 5, 179-187
Open AccessCost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
Peer reviewed article authored by (Anand A Dalal, Meaghan St Charles, Hans V Petersen, et al). Read article or submit your manuscript for publishing.
- 1 November 2009
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (11) , 2574-2583
Association between previous health care use and initiation of inhaled corticosteroid and long-acting β2-adrenergic agonist combination therapy among US patients with asthma
- 1 November 2009
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (11) , 2574-2583
Association between previous health care use and initiation of inhaled corticosteroid and long-acting β2-adrenergic agonist combination therapy among US patients with asthma
- 24 September 2009
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 25 (11) , 2729-2735
Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population
Chronic obstructive pulmonary disease (COPD) is a highly prevalent condition with high morbidity and mortality among older and disabled adults. Few studies have examined the comparative effectiveness of maintenance therapies for chronic obstructive pulmonary disease (COPD) in this vulnerable population. The study aims to compare healthcare resource utilization associated with hospitalization or emergency department (ED) visits between FDA-approved inhaled corticosteroid/long-acting beta-agonist combinations [fluticasone propionate 250 microg/salmeterol 50 microg combination (FSC)] and anticholinergic treatments (ATC) in managed-care Medicare beneficiaries with COPD. Data from the Integrated Health Care Information Systems (IHCIS) National Managed Care Benchmark Database was used in this retrospective, observational cohort study. The cohort consisted of managed-care Medicare beneficiaries with a diagnosis of COPD [International Classification of Disease, 9th revision, Clinical Modification (ICD-9-CM) codes 491.xx, 492.xx, or 496.xx] without evidence of comorbid asthma (ICD-9-CM 493.xx) who received treatment with FSC or ATC between 2003 and 2005. Cox proportional hazards regression models were conducted to examine the risk of all-cause and COPD-related hospitalizations and emergency department (ED) visits. COPD patients treated with FSC had a 18% lower risk of a COPD-related hospitalization (HR = 0.82; 95% CI = 0.75, 0.89) and an ED visit (HR = 0.82; 95% CI = 0.76, 0.89) compared to patients treated with ATC. Findings were similar for all-cause utilization (hospitalization HR = 0.83; 95% CI = 0.78, 0.88; ED visit HR = 0.84; 95% CI = 0.80, 0.88). FSC is associated with a lower risk of COPD-related exacerbation events relative to ATC in managed-care Medicare beneficiaries with COPD. Findings from this study are only generalizable to managed-care Medicare beneficiaries residing in the community.
- 24 September 2009
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 25 (11) , 2729-2735
Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population
Chronic obstructive pulmonary disease (COPD) is a highly prevalent condition with high morbidity and mortality among older and disabled adults. Few studies have examined the comparative effectiveness of maintenance therapies for chronic obstructive pulmonary disease (COPD) in this vulnerable population. The study aims to compare healthcare resource utilization associated with hospitalization or emergency department (ED) visits between FDA-approved inhaled corticosteroid/long-acting beta-agonist combinations [fluticasone propionate 250 microg/salmeterol 50 microg combination (FSC)] and anticholinergic treatments (ATC) in managed-care Medicare beneficiaries with COPD. Data from the Integrated Health Care Information Systems (IHCIS) National Managed Care Benchmark Database was used in this retrospective, observational cohort study. The cohort consisted of managed-care Medicare beneficiaries with a diagnosis of COPD [International Classification of Disease, 9th revision, Clinical Modification (ICD-9-CM) codes 491.xx, 492.xx, or 496.xx] without evidence of comorbid asthma (ICD-9-CM 493.xx) who received treatment with FSC or ATC between 2003 and 2005. Cox proportional hazards regression models were conducted to examine the risk of all-cause and COPD-related hospitalizations and emergency department (ED) visits. COPD patients treated with FSC had a 18% lower risk of a COPD-related hospitalization (HR = 0.82; 95% CI = 0.75, 0.89) and an ED visit (HR = 0.82; 95% CI = 0.76, 0.89) compared to patients treated with ATC. Findings were similar for all-cause utilization (hospitalization HR = 0.83; 95% CI = 0.78, 0.88; ED visit HR = 0.84; 95% CI = 0.80, 0.88). FSC is associated with a lower risk of COPD-related exacerbation events relative to ATC in managed-care Medicare beneficiaries with COPD. Findings from this study are only generalizable to managed-care Medicare beneficiaries residing in the community.
- 15 February 2009
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (4) , 366-372
Health care use in depressed, elderly, cardiac patients and the effect of antidepressant use
Purpose. The association between a diagnosis of depression after a thromboembolic event (TEE) and an increase in acute health care use was examined.
- 15 February 2009
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (4) , 366-372
Health care use in depressed, elderly, cardiac patients and the effect of antidepressant use
Purpose. The association between a diagnosis of depression after a thromboembolic event (TEE) and an increase in acute health care use was examined.
- 1 January 2009
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 12 (3) , 171-179
Burden of blood transfusion in knee and hip surgery in the US and Belgium
(2009). Burden of blood transfusion in knee and hip surgery in the US and Belgium. Journal of Medical Economics: Vol. 12, No. 3, pp. 171-179. doi: 10.3111/13696990903172760
- 1 January 2009
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 12 (3) , 171-179
Burden of blood transfusion in knee and hip surgery in the US and Belgium
(2009). Burden of blood transfusion in knee and hip surgery in the US and Belgium. Journal of Medical Economics: Vol. 12, No. 3, pp. 171-179. doi: 10.3111/13696990903172760
- Open Access
- 1 January 2009
- Published by Wiley in Cardiology Research and Practice
- Vol. 2009 (1) , 194528
Depression Following Thrombotic Cardiovascular Events in Elderly Medicare Beneficiaries: Risk of Morbidity and Mortality
Purpose. Depression and antidepressant use may independently increase the risk of acute myocardial infarction and mortality in adults. However, no studies have looked at the effect of depression on a broader thrombotic event outcome, assessed antidepressant use, or evaluated elderly adults. Methods. A cohort of 7,051 community‐dwelling elderly beneficiaries who experienced a thrombotic cardiovascular event (TCE) were pooled from the 1997 to 2002 Medicare Current Beneficiary Survey and followed for 12 months. Baseline characteristics, antidepressant utilization, and death were ascertained from the survey, while indexed TCE, recurrent TCE, and depression (within 6 months of indexed TCE) were taken from ICD‐9 codes on Medicare claims. Time to death and first recurrent TCE were assessed using descriptive and multivariate statistics. Results. Of the elders with a depression claim, 71.6% had a recurrent TCE and 4.7% died within 12 months of their indexed TCE, compared to 67.6% and 3.9% of those elders without a depression claim. Of the antidepressant users, 72.6% experienced a recurrent TCE and 3.9% died, compared to 73.7% and 4.6% in the subset of selective serotonin reuptake inhibitor (SSRI) users. Depression was associated with a shorter time to death (P = .008) in the unadjusted analysis. However, all adjusted comparisons revealed no effect by depression, antidepressant use, or SSRI use. Conclusions. Depression was not associated with time to death or recurrent TCEs in this study. Antidepressant use, including measures of any antidepressant use and SSRI use, was not associated with shorter time to death or recurrent TCE.
- 1 January 2009
- Published by Wiley in Cardiology Research and Practice
- Vol. 2009 (1) , 194528
Open AccessDepression Following Thrombotic Cardiovascular Events in Elderly Medicare Beneficiaries: Risk of Morbidity and Mortality
Purpose. Depression and antidepressant use may independently increase the risk of acute myocardial infarction and mortality in adults. However, no studies have looked at the effect of depression on a broader thrombotic event outcome, assessed antidepressant use, or evaluated elderly adults. Methods. A cohort of 7,051 community‐dwelling elderly beneficiaries who experienced a thrombotic cardiovascular event (TCE) were pooled from the 1997 to 2002 Medicare Current Beneficiary Survey and followed for 12 months. Baseline characteristics, antidepressant utilization, and death were ascertained from the survey, while indexed TCE, recurrent TCE, and depression (within 6 months of indexed TCE) were taken from ICD‐9 codes on Medicare claims. Time to death and first recurrent TCE were assessed using descriptive and multivariate statistics. Results. Of the elders with a depression claim, 71.6% had a recurrent TCE and 4.7% died within 12 months of their indexed TCE, compared to 67.6% and 3.9% of those elders without a depression claim. Of the antidepressant users, 72.6% experienced a recurrent TCE and 3.9% died, compared to 73.7% and 4.6% in the subset of selective serotonin reuptake inhibitor (SSRI) users. Depression was associated with a shorter time to death (P = .008) in the unadjusted analysis. However, all adjusted comparisons revealed no effect by depression, antidepressant use, or SSRI use. Conclusions. Depression was not associated with time to death or recurrent TCEs in this study. Antidepressant use, including measures of any antidepressant use and SSRI use, was not associated with shorter time to death or recurrent TCE.